ArticleScientific reports2026
Discovery of age and blood group associated variability in nattokinase mediated thrombolysis and its relevance to cardiovascular management.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The post-COVID period has been accompanied by a notable rise in cardiovascular disease (CVD), emphasizing the importance of evaluating thrombolytic agents across heterogeneous populations. Although nattokinase (NK) is known for its fibrinolytic properties, systematic data on its clot dissolution efficiency and clot dissolution time (CDT) in the Indian population remain limited. Hence, this study examined NK-mediated thrombolysis across ABO/RhD blood groups, age strata, and gender supported by molecular docking and ultrastructural analyses. A total of 1,796 blood samples encompassing all eight ABO/RhD blood groups were collected from individuals aged 10–70 years from the Saurashtra region. In vitro clot lysis assays were used to quantify CDT following NK treatment, while scanning electron microscopy (SEM) and molecular docking & dynamic were employed to investigate NK–fibrin–RhD interactions. Significant variation in CDT was observed across blood groups, with the longest dissolution time recorded in AB− females (2660 s) and the shortest in O+ males (1510 s). Four-way ANOVA analysis revealed a significant three-way interaction effect of age group x ABO blood group x RhD factor (p = 0.005), whereas the four-way interaction including gender was not significant (p = 1.000). CDT trends were further validated using an independent cohort of 562 samples collected from nine distinct locations across India, which showed consistent patterns. Molecular interaction analysis revealed that the RhD–NK–fibrin complex displayed substantially higher binding affinity (− 1813.9 kcal/mol) than the NK–fibrin complex alone (− 733.3 kcal/mol), aligned with enhanced clot dissolution efficiency observed in SEM analyses. In conclusion, NK-mediated CDT is not uniform across blood groups and is influenced by age and blood group antigen composition. These findings recommend large-scale in vivo validation studies to optimize NK dosing across diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.